Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men

BJU International

Volumn 100, Issue 3, 2007, Pages 685-690

  Shimizu, Yousuke ^a   Segawa, Takehiko ^a   Inoue, Takahiro ^a   Shiraishi, Taizo ^b   Yoshida, Toru ^a   Toda, Yoshinobu ^a   Yamada, Tomomi ^c   Kinukawa, Naoko ^c   Terada, Naoki ^a   Kobayashi, Takashi ^a   Kinoshita, Hidefumi ^d   Kamoto, Toshiyuki ^a   Nakamura, Eijiro ^a   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Akt; Androgen receptor; Phosphorylated Akt; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; KI 67 ANTIGEN; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY;

ADENOCARCINOMA; AGED; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; KI-67 ANTIGEN; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHORYLATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 34547645592     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07014.x     Document Type: Article

References (32)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999 49 : 8 31
2. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994 331 : 996 1004
3. Isaacs JT. Apoptosis: translating theory to therapy for prostate cancer. J Natl Cancer Inst 2000 92 : 1367 9
4. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997 275 : 1943 7
5. Steck PA, Pershouse MA, Jasser SA et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997 15 : 356 62
6. Stambolic V, Suzuki A, de la Pompa JL et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998 95 : 29 39
7. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt-1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 2001 276 : 38349 52
8. Cho H, Mu J, Kim JK et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt-2 (PKBβ). Science 2001 292 : 1728 31
9. Easton RM, Cho H, Roovers K et al. Role for Akt-3/protein kinase Bγ in attainment of normal brain size. Mol Cell Biol 2005 25 : 1869 78
10. Majumder PK, Yeh JJ, George DJ et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci USA 2003 100 : 7841 6
11. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999 59 : 2891 7
12. Graff JR, Konicek BW, McNulty AM et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000 275 : 24500 5
13. Manin M, Baron S, Goossens K et al. Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J 2002 366 : 729 36
14. Liao Y, Grobholz R, Abel U et al. Increase of AKT/PKB expression correlates with Gleason pattern in human prostate cancer. Int J Cancer 2003 107 : 676 80
15. Malik SN, Brattain M, Ghosh PM et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002 8 : 1168 71
16. Kreisberg JI, Malik SN, Prihoda TJ et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004 64 : 5232 6
17. Ayala G, Thompson T, Yang G et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004 10 : 6572 8
18. Le Page C, Koumakpayi IH, Alam-Fahmy M, Mes-Masson AM, Saad F. Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer 2006 94 : 1906 12
19. Shiraishi T, Muneyuki T, Fukutome K et al. Mutations of ras genes are relatively frequent in Japanese prostate cancers: pointing to genetic differences between populations. Anticancer Res 1998 18 : 2789 92
20. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005 41 : 834 45
21. Inoue T, Segawa T, Shiraishi T et al. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005 66 : 332 7
22. Fenic I, Franke F, Failng K, Steger K, Woenckhaus J. Expression of PTEN in malignant and non-malignant human prostate tissues: comparison with p27 protein expression. J Pathol 2004 203 : 559 66
23. Kandel ES, Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 1999 253 : 210 29
24. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000 404 : 782 7
25. Ghosh PM, Malik SN, Bedolla RG et al. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer 2005 12 : 119 34
26. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 1998 12 : 502 13
27. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999 344 : 427 31
28. Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK, Witte ON. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci USA 2006 103 : 7789 94
29. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004 28 : 928 34
30. Schafer W, Funke PJ, Kunde D, Rausch U, Wennemuth G, Stutzer H. Intensity of androgen and epidermal growth factor receptor immunoreactivity in sample of radical prostatectomy as prognostic indicator: correlation with clinical data of long-term observations. J Urol 2006 176 : 532 7
31. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984 5 : 545 57
32. Iwamoto T, Yanase T, Koh E et al. [Reference ranges of serum total and free testosterone in Japanese male adults]. Nippon Hinyokika Gakkai Zasshi 2004 95 : 751 60